The Francis Crick Institute and the Royal Marsden Foundation Trust are spearheading the MANIFEST project with £21.9 million in government and industry funding.
After the latest funding and merger, OnKure will have enough resources to support operations into Q4 2026, including development of its PI3Kα inhibitors.
NEW YORK – AstraZeneca on Monday said it has inked an exclusive license agreement with Shijiazhuang, China-based CSPC Pharmaceutical Group to develop an early-stage small molecule lipoprotein(a) ...
NEW YORK – Avistone Biotechnology said on Friday that it will begin studying its c-MET inhibitor ANS01 in a Canada-based Phase I trial enrolling patients with MET-altered solid tumors. The ...